title: High pretreatment interleukin-10 is an independent predictor of poor failure-free survival in patients with Hodgkin's lymphoma.
abstract: OBJECTIVE
  The aim of this study was to investigate the relationship of pretreatment serum IL-10 (sIL-10) levels with known prognostic factors and with failure-free survival (FFS) in patients with Hodgkin's lymphoma (HL).
  
  
  METHODS
  Interleukin-10 (IL-10) levels were measured in the sera of 36 untreated patients with HL and were subsequently correlated with clinical and laboratory prognostic parameters as well as with FFS.
  
  
  RESULTS
  36 untreated HL patients (21 men, median age 31 (18-62) years) were studied. Of the subjects, 19 (52.7%) had elevated IL-10 levels (> or = 10 pg/ml). High IL-10 correlated with bulky disease, high serum lactate dehydrogenase (LDH) and leukocytosis (P = 0.015 for all three variables). High IL-10 (P = 0.015) and low serum albumin (P = 0.001) were associated with worse FFS, but only high IL-10 emerged as an independent predictor of inferior FFS in multivariate analysis (P = 0.04, hazard ratio 2.21, 95% CI 1.12-14.67). Median FFS of IL-10-positive patients (30 (12-47) months) was significantly shorter compared to that of IL-10-negative ones (39 (12-58) months, log-rank test P = 0.0185).
  
  
  CONCLUSIONS
  IL-10 was found to be elevated in approximately half of untreated patients with HL, to correlate with bulky disease, high LDH and leukocytosis and to be an independent predictor of FFS.
authors.affiliation: Haematology-Oncology Unit, Third University Department of Medicine, Sotiria Hospital, 152 Mesogion Avenue, Athens 11527, Greece.
authors.forename: Eleanna V
authors.initials: EV
authors.lastname: Salgami
authors.forename: Stamatis P
authors.initials: SP
authors.lastname: Efstathiou
authors.forename: Vasilios
authors.initials: V
authors.lastname: Vlachakis
authors.forename: Eleftheria V
authors.initials: EV
authors.lastname: Sekara
authors.forename: Konstantinos N
authors.initials: KN
authors.lastname: Syrigos
authors.forename: Paraskevi P
authors.initials: PP
authors.lastname: Roussou
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016022:Case-Control Studies; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000097:blood / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012709:Serum Albumin / Q000378:metabolism
chemical_list: D012709:Serum Albumin; D016753:Interleukin-10; D007770:L-Lactate Dehydrogenase